Mentioning the unveiling of Human Influenza Vaccine, Vice chairman of Alborz Chamber of Commerce stated: if the conditions for the mass production of this product are met, this can annually prevent $100 M currency expenditure.

According to the reports from the public relations office of Alborz Province’ Chamber of Commerce, Industries, Mines, and Agriculture, mentioning the big achievement of manufacturing first domestic seasonal human influenza vaccine with the name “Fluguard”, Dr. Amir Farshchi added: this vaccine is one of the most important and strategic vaccines in world’s health and medical systems.

Considering that yet many of the developed countries in the world have not been able to manufacture this vaccine, he said: currently only one company in the world is the producer of the recombinant Influenza vaccine, making us the second manufacturer in the world.

Vice chairman of Alborz Chamber of Commerce added: strategically, influenza vaccine plays an important role in a country’s health system and fortunately we have been able for the first time in pharmaceutical industry’s history to domesticate the science of its production.

Mentioning that the technological collaboration between Aryogen Pharmed and Nivad Pharmed has led to the production of seasonal influenza vaccine, he said: currently based on the studies and regarding the simultaneous outbreak of flu and corona in cold seasons, administering influenza vaccine can potentially reduce the risk of contracting corona in the populations. 

Farshchi said before the domestication of influenza vaccine production, the need of the country had to be satisfied via import, hence high expenses. Following the outbreak of corona worldwide, there has been a shortage in influenza vaccine, consequently purchase and import of this product is made even harder. The domestic manufacturing of this vaccine makes the value of such achievement even more noticeable. 

He continued: manufacturing influenza vaccine is actually a sequel to previous developments in order to complete a chain of technological advancements made in Aryogen.

Farshchi said: fortunately this company has been able to produce influenza vaccine after successful production and marketing of Temziva- which is used for treatment of corona patients- in 2020 and in that way has made a great step towards the health and well-being of the country’s population.

In response to the question considering the possibility of the export of this vaccine to other parts of the world, he said: regarding the production capacities available now, after providing the country’s needs, we can consider planning and attempt to accept orders for export.

About the pharmaceutical products planned by Aryogen Pharmed to be produced in 1400, Farshchi said: at least two more products will be introduced to the market by the end of the year. One of them is a monoclonal antibody used for the treatment of rheumatoid arthritis, and another one which has finished the final phase and we are hopeful to finish the clinical trials by the end of the year, is effective in the treatment of blood diseases.